GRAVES DISEASE

This early-stage trial tests a new biologic drug called MER511 in 100 adults with Graves' disease. The main goal is to check safety and side effects, and to see how the body handles the drug when given by IV or injection. Participants must be on stable thyroid medication. The stu…

This study tests whether BHV-1300 can help adults with Graves' disease achieve normal thyroid function without antithyroid drugs. Participants receive either BHV-1300 or a placebo via injection. The main goal is to see if more people on BHV-1300 have normal thyroid hormone levels…

This trial tests a new drug called IMVT-1402 for adults with Graves' disease, a condition where the thyroid is overactive. The study will include 210 participants who still have high thyroid levels despite taking standard medications. Participants will receive either one of two d…

This phase 2 trial tests two doses of rilzabrutinib, an oral drug, in 30 adults with Graves' disease (with or without eye problems). The main goal is to see if the drug lowers high thyroid hormone levels over 16 weeks. Researchers will also monitor safety and side effects.

This phase 2b trial tests an experimental drug called IMVT-1402 in 240 adults with Graves' disease whose thyroid is still overactive despite standard treatment. The goal is to see if the drug can help patients achieve normal thyroid hormone levels and stop taking antithyroid medi…

This early study is testing a new drug called BHV-1300 in 15 people with Graves' disease. The main goal is to see if the drug is safe and to check how it affects certain markers of the disease. This is a phase 1 trial, so it's one of the first steps in testing this treatment in h…

This early-phase trial tests HN2301, a new type of CAR-T therapy given directly into the blood, for people with refractory Graves' disease—a thyroid condition that doesn't respond well to standard treatments. The therapy reprograms the body's own immune cells to target and calm t…

This early-stage trial tests a single injection of a new drug called GenSci098 in 24 adults with Graves' disease, a condition where the thyroid is overactive. The main goal is to check safety and side effects over about 5 months. Researchers will also measure how the drug moves t…

This study looks at whether giving Lugol's solution before removing the thyroid gland can lower the chance of two common surgery complications: low calcium levels from damaged parathyroid glands and vocal cord weakness from nerve injury. About 182 adults with overactive thyroid f…

This pilot study tests whether adding high-dose vitamin D to standard methimazole therapy helps control thyroid function and antibodies in children aged 9-17 newly diagnosed with Graves' disease. The main goal is to see if a larger trial is possible by measuring recruitment, adhe…

This early-phase trial tests a single infusion of genetically modified immune cells (CAR-T cells) in 4 people with refractory Graves' disease, a thyroid condition that doesn't respond well to standard medication. The cells target two proteins (CD19 and BCMA) to reset the immune s…

This pilot study will test the safety of thyroid artery embolization (TAE) in 10 UK patients with benign thyroid nodules or goitre. TAE is a minimally invasive procedure that blocks blood flow to the thyroid gland using tiny particles, causing it to shrink. The goal is to see if …

This study tests a computer model called OptiThyDose that helps doctors find the best dose of thyroid medication for children with congenital hypothyroidism or Graves' disease. The model uses past lab results to keep thyroid hormone levels in a healthy range. About 150 children w…

This study tests a software called Glandy HYPER that uses artificial intelligence to detect thyrotoxicosis—a dangerous overactive thyroid state—in people with Graves' disease. The AI analyzes resting heart rate data from wearable devices like smartwatches and compares it with sta…

This study tests whether a person-centred care (PCC) programme, delivered by phone and online, can help people with Graves' disease feel better mentally and return to work. 220 adults with first-time Graves' disease will be randomly assigned to receive either usual care or usual …

This study tests whether a special course on mental fatigue can help people with Graves' disease who struggle with ongoing brain tiredness, trouble focusing, and memory issues. About 96 adults aged 18-72 with stable thyroid levels will either take the course plus standard care or…

This study looks at 100 people with Graves disease to see if inflammation and thyroid antibodies are linked to changes in the eye's nerve layer and macula. Researchers will compare eye scans (OCT) and blood tests between patients with and without eye involvement, plus healthy con…

This study looks at how changing thyroid hormone levels affect the way the body uses sugar and fat. Researchers will study people with Graves' disease (whose thyroid hormones are too high) and people with thyroid cancer (whose hormones are intentionally raised). Participants will…

This study tests a special collar worn around the neck that measures radiation exposure in people with thyroid cancer or Graves' disease receiving radioactive iodine therapy. The goal is to see if this device gives more accurate dosing information than current methods, potentiall…

This study investigates why some people with Graves' disease continue to feel mentally fatigued even after their thyroid levels return to normal. Researchers will compare blood and spinal fluid from 180 participants—60 with mental fatigue, 60 without, and 60 healthy controls—to f…